

# Diego Ferone

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3070760/diego-ferone-publications-by-citations.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260  
papers

9,977  
citations

54  
h-index

89  
g-index

283  
ext. papers

11,430  
ext. citations

5.1  
avg, IF

5.55  
L-index

#	Paper	IF	Citations
260	Systemic complications of acromegaly: epidemiology, pathogenesis, and management. <i>Endocrine Reviews</i> , <b>2004</b> , 25, 102-52	27.2	880
259	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1604-20	10.3	363
258	Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 2664-72	5.6	291
257	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , <b>2016</b> , 103, 119-24	5.6	258
256	Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 2779-86	5.6	213
255	Dopamine receptor expression and function in corticotroph pituitary tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 2452-62	5.6	210
254	Well-differentiated pancreatic tumor/carcinoma: insulinoma. <i>Neuroendocrinology</i> , <b>2006</b> , 84, 183-8	5.6	191
253	Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 876-83	5.6	189
252	Effect of octreotide pretreatment on surgical outcome in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 3308-14	5.6	184
251	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , <b>2016</b> , 103, 139-43	5.6	153
250	Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 193-9	5.6	137
249	Effect of different dopaminergic agents in the treatment of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 518-23	5.6	121
248	Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 2777-81	5.6	113
247	Prediction of efficacy of octreotide therapy in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1996</b> , 81, 2356-62	5.6	112
246	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, 505-518	5.7	110
245	Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 17-23	5.6	101
244	Immunoreactivity score using an anti-ss2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E66-71	5.6	99

243	Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 1412-7	5.6	96
242	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. <i>Acta Diabetologica</i> , <b>2009</b> , 46, 85-95	3.9	95
241	Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 1551-7	5.6	94
240	Peptide receptor therapies in neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , <b>2009</b> , 32, 360-9	5.2	92
239	Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1993</b> , 77, 790-3	5.6	92
238	Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. <i>Neuroendocrinology</i> , <b>2008</b> , 87, 31-9	5.6	90
237	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , <b>2007</b> , 156 Suppl 1, S13-S21	6.5	90
236	Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , <b>2015</b> , 172, R227-39	6.5	89
235	Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 4099-103	5.6	89
234	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	88
233	Prostatic hyperplasia: an unknown feature of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 775-9	5.6	86
232	Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. <i>European Journal of Endocrinology</i> , <b>1998</b> , 138, 286-93	6.5	86
231	Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 3132-40	5.6	85
230	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 515-24	3.4	84
229	In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. <i>Endocrinology</i> , <b>1999</b> , 140, 373-80	4.8	82
228	ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. <i>Neuroendocrinology</i> , <b>2017</b> , 105, 201-211	5.6	80
227	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 3231-44	5.6	79
226	Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5022-32	12.9	78

225	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , <b>1997</b> , 47, 23-8	3.4	77
224	Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. <i>Skull Base</i> , <b>1999</b> , 9, 109-17		77
223	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , <b>2017</b> , 105, 245-254	5.6	69
222	Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 1592-9	5.6	69
221	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , <b>1999</b> , 1, 115-20	4.3	69
220	Cabergoline plus lanreotide for ectopic Cushing's syndrome. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2457-8	59.2	68
219	Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 284-90	5.2	67
218	High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2010</b> , 20, 633-40	4.5	64
217	Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>1999</b> , 22, 40-7	5.2	64
216	Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 4493-502	5.6	63
215	Somatostatin receptor ligands in the treatment of acromegaly. <i>Pituitary</i> , <b>2017</b> , 20, 100-108	4.3	62
214	Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1518-23	5.6	61
213	The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. <i>Journal of Molecular Endocrinology</i> , <b>2009</b> , 42, 361-70	4.5	60
212	Reversibility of joint thickening in acromegalic patients: an ultrasonography study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 2121-5	5.6	60
211	Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. <i>Endocrine</i> , <b>2017</b> , 57, 214-219	4	59
210	Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. <i>European Journal of Endocrinology</i> , <b>2013</b> , 169, 767-72	6.5	59
209	Interactions between vitamin D and IGF-I: from physiology to clinical practice. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 457-63	3.4	59
208	Dopamine receptor expression and function in corticotroph ectopic tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 65-9	5.6	58

207	Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1999</b> , 84, 1986-91	5.6	58
206	Managing Cushing's disease: the state of the art. <i>Endocrine</i> , <b>2014</b> , 47, 9-20	4	52
205	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. <i>Neuroendocrinology</i> , <b>2009</b> , 90, 209-13	5.6	51
204	Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , <b>2009</b> , 71, 237-45	3.4	51
203	Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1719-26	5.6	51
202	Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. <i>Clinical Endocrinology</i> , <b>1999</b> , 51, 611-8	3.4	51
201	Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2002</b> , 283, E1056-66	6	50
200	Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 905-9	5.6	49
199	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , <b>2017</b> , 58, 349-359	4	48
198	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 817-23	5.2	48
197	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, 871-881	5.7	47
196	The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 3854-60	5.6	47
195	Effect of growth hormone on cardiac function. <i>Hormone Research</i> , <b>1997</b> , 48 Suppl 4, 38-42		46
194	Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. <i>Pituitary</i> , <b>2008</b> , 11, 93-102	4.3	44
193	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , <b>2000</b> , 53, 13-9	3.4	43
192	Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor. <i>Neuroendocrinology</i> , <b>2016</b> , 103, 452-9	5.6	42
191	Cost-of-illness study in acromegalic patients in Italy. <i>Journal of Endocrinological Investigation</i> , <b>2004</b> , 27, 1034-9	5.2	42
190	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, 495-504	5.7	41

189	Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. <i>Endocrinology</i> , <b>2013</b> , 154, 4715-25	4.8	40
188	Diffuse endocrine system, neuroendocrine tumors and immunity: what's new?. <i>Neuroendocrinology</i> , <b>2012</b> , 95, 267-76	5.6	40
187	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. <i>Clinical Endocrinology</i> , <b>2000</b> , 52, 437-45	3.4	40
186	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, 453-461	6.5	39
185	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, 691-704	5.7	39
184	Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. <i>Clinical Endocrinology</i> , <b>2012</b> , 76, 407-14	3.4	39
183	The metabolic profile in active acromegaly is gender-specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E51-9	5.6	38
182	Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas. <i>Molecular Neurobiology</i> , <b>2017</b> , 54, 4879-4895	6.2	38
181	Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1069, 129-44	6.5	38
180	Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. <i>Journal of Endocrinological Investigation</i> , <b>2013</b> , 36, 38-43	5.2	38
179	Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. <i>Journal of Cellular and Molecular Medicine</i> , <b>2012</b> , 16, 1563-72	5.6	37
178	Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, E165-72	5.6	37
177	Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2005</b> , 289, E1044-50	6	37
176	Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 445-9	5.2	36
175	The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , <b>1999</b> , 22, 176-83	5.2	35
174	Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. <i>Clinical Endocrinology</i> , <b>2004</b> , 61, 138-44	3.4	34
173	Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 3754-61	5.6	34
172	Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease. <i>European Journal of Endocrinology</i> , <b>2006</b> , 154, 813-8	6.5	33

171	Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 326-31	5.2	33
170	Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?. <i>Pituitary</i> , <b>2015</b> , 18, 583-91	4.3	32
169	In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. <i>Pituitary</i> , <b>2011</b> , 14, 141-7	4.3	32
168	Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 248-52	5.6	32
167	Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1998</b> , 83, 3790-4	5.6	32
166	Cardiovascular aspects in acromegaly: effects of treatment. <i>Metabolism: Clinical and Experimental</i> , <b>1996</b> , 45, 57-60	12.7	32
165	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , <b>2016</b> , 51, 131-9	4	31
164	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2009-2018	5.6	31
163	Pegvisomant in acromegaly: why, when, how. <i>Journal of Endocrinological Investigation</i> , <b>2007</b> , 30, 693-9	5.2	31
162	Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 2119-24	5.6	31
161	Somatostatin receptor distribution and function in immune system. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36 Suppl 1, S68-77	3.3	31
160	CV 205-502 treatment in therapy-resistant acromegalic patients. <i>European Journal of Endocrinology</i> , <b>1995</b> , 132, 559-64	6.5	31
159	Zebrafish as an innovative model for neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, R67-83	5.7	30
158	Novel chimeric somatostatin analogs: facts and perspectives. <i>European Journal of Endocrinology</i> , <b>2007</b> , 156 Suppl 1, S23-S28	6.5	30
157	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2454-2464	5.6	29
156	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , <b>2016</b> , 174, 651-62	6.5	29
155	Primary empty sella: Why and when to investigate hypothalamic-pituitary function. <i>Journal of Endocrinological Investigation</i> , <b>2010</b> , 33, 343-6	5.2	29
154	Bone mineral density and circulating cytokines in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 688-93	5.2	29

153	Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 458-68	8.8	27
152	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , <b>2014</b> , 46, 181-98	4	27
151	Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. <i>Journal of Endocrinology</i> , <b>2010</b> , 207, 309-17	4.7	27
150	Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. <i>Hormone Research</i> , <b>1993</b> , 40, 149-55		27
149	Pharmacotherapy or surgery as primary treatment for acromegaly?. <i>Drugs and Aging</i> , <b>2000</b> , 17, 81-92	4.7	26
148	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , <b>2017</b> , 56, 633-638	4	25
147	Failure of long-term therapy with sodium valproate in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , <b>1997</b> , 20, 387-92	5.2	25
146	Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. <i>Kidney International</i> , <b>2008</b> , 74, 937-45	9.9	24
145	Physiological and pathophysiological role of somatostatin receptors in the human thymus. <i>European Journal of Endocrinology</i> , <b>2000</b> , 143 Suppl 1, S27-34	6.5	24
144	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , <b>2017</b> , 57, 366-375	4	23
143	Sympathovagal imbalance in acromegalic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 115-20	5.6	23
142	In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 469-77	3.4	22
141	Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. <i>Gynecological Endocrinology</i> , <b>1994</b> , 8, 175-81	2.4	22
140	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects		22
139	Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. <i>Journal of Zhejiang University: Science B</i> , <b>2009</b> , 10, 323-30	4.5	21
138	Initial staging of lymphoma with octreotide and other receptor imaging agents. <i>Seminars in Nuclear Medicine</i> , <b>2005</b> , 35, 176-85	5.4	21
137	Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. <i>Current Molecular Medicine</i> , <b>2013</b> , 13, 555-71	2.5	21
136	Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up. <i>Clinical Endocrinology</i> , <b>2009</b> , 71, 220-5	3.4	20



135	Age-related decrease of somatostatin receptor number in the normal human thymus. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2000</b> , 279, E791-8	6	20
134	Pituitary image: pituicytoma. <i>Pituitary</i> , <b>2015</b> , 18, 592-7	4.3	19
133	Regulation of prostate cancer cell proliferation by somatostatin receptor activation. <i>Molecular and Cellular Endocrinology</i> , <b>2010</b> , 315, 254-62	4.4	19
132	The pathology of the ulnar nerve in acromegaly. <i>European Journal of Endocrinology</i> , <b>2008</b> , 159, 369-73	6.5	19
131	Lymphocyte subset pattern in acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>2002</b> , 25, 125-8	5.2	19
130	In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. <i>Journal of Endocrinological Investigation</i> , <b>2001</b> , 24, 522-8	5.2	19
129	Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. <i>Hormone Research</i> , <b>1995</b> , 44, 222-8		19
128	Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. <i>Journal of Endocrinology</i> , <b>1997</b> , 155 Suppl 1, S33-7; discussion S39	4.7	19
127	Identification of a novel mutation in exon 1 of androgen receptor gene in an azoospermic patient with mild androgen insensitivity syndrome: case report and literature review. <i>Fertility and Sterility</i> , <b>2011</b> , 96, 1165-9	4.8	18
126	Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. <i>European Journal of Endocrinology</i> , <b>2007</b> , 156 Suppl 1, S37-S43	6.5	18
125	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. <i>Oncotarget</i> , <b>2017</b> , 8, 41044-41063	3.3	18
124	Vitamin D and Lung Outcomes in Elderly COVID-19 Patients. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	18
123	Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. <i>International Journal of Endocrinology</i> , <b>2014</b> , 2014, 753524	2.7	17
122	Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone. <i>Journal of Endocrinological Investigation</i> , <b>2009</b> , 32, 308-12	5.2	17
121	Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. <i>Thoracic Surgery Clinics</i> , <b>2014</b> , 24, 277-83	3.1	16
120	Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?. <i>Endocrine</i> , <b>2016</b> , 53, 58-62	4	16
119	Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. <i>Journal of Zhejiang University: Science B</i> , <b>2011</b> , 12, 163-73	4.5	15
118	Cardiac effect of thyrotoxicosis in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1426-32	5.6	15

117	Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. <i>Endocrine</i> , <b>2018</b> , 61, 533-541	4	15
116	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , <b>2018</b> , 62, 215-233	4	14
115	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , <b>2018</b> , 97, 59-61	7.5	14
114	KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?. <i>Endocrine</i> , <b>2017</b> , 57, 494-502	4	14
113	Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives. <i>Annales DjEndocrinologie</i> , <b>2015</b> , 76, 43-58	1.7	14
112	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	14
111	Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	13
110	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. <i>Molecular and Cellular Endocrinology</i> , <b>2014</b> , 382, 860-70	4.4	13
109	Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. <i>European Journal of Endocrinology</i> , <b>2014</b> , 170, 247-54	6.5	13
108	Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments. <i>Journal of Andrology</i> , <b>2008</b> , 29, 580-5		13
107	Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. <i>Clinical Endocrinology</i> , <b>1999</b> , 51, 159-64	3.4	13
106	Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. <i>Pituitary</i> , <b>2019</b> , 22, 89-99	4.3	13
105	Role of dopamine receptors in normal and tumoral pituitary corticotrophic cells and adrenal cells. <i>Neuroendocrinology</i> , <b>2010</b> , 92 Suppl 1, 17-22	5.6	12
104	Computed tomography colonography in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 218-22	5.6	12
103	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , <b>1998</b> , 49, 77-84	3.4	12
102	Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. <i>Radiologia Medica</i> , <b>2011</b> , 116, 781-92	6.5	11
101	Hormone receptors analysis in idiopathic progressive subglottic stenosis. <i>Laryngoscope</i> , <b>2018</b> , 128, E72-E77	3	11
100	Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. <i>Endocrine</i> , <b>2016</b> , 51, 524-33	4	10

99	Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. <i>Pituitary</i> , <b>2019</b> , 22, 552-560	4.3	10
98	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , <b>2020</b> , 69, 441-450		10
97	Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case for. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 613-5	5.2	10
96	Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. <i>Journal of Endocrinological Investigation</i> , <b>2005</b> , 28, 166-9	5.2	10
95	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. <i>Clinical Endocrinology</i> , <b>1996</b> , 45, 157-66	3.4	10
94	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , <b>2015</b> , 38, 193-259	5.2	9
93	Octreotide-Resistant Acromegaly: Challenges and Solutions. <i>Therapeutics and Clinical Risk Management</i> , <b>2020</b> , 16, 379-391	2.9	9
92	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , <b>2020</b> , 25, 259-265	5.7	9
91	Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2019</b> , 20, 365-381	10.5	9
90	Sonographic depiction of trigger fingers in acromegaly. <i>Journal of Ultrasound in Medicine</i> , <b>2009</b> , 28, 1441-6		9
89	Fixity of vocal cords and laryngocele in acromegaly. <i>Journal of Endocrinological Investigation</i> , <b>1997</b> , 20, 672-4	5.2	9
88	Somatostatin receptor scintigraphy in thoracic diseases. <i>Journal of Endocrinological Investigation</i> , <b>2007</b> , 30, 889-902	5.2	9
87	Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study. <i>Thyroid Research</i> , <b>2008</b> , 1, 2	2.4	9
86	Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas. <i>European Journal of Endocrinology</i> , <b>1995</b> , 133, 38-47	6.5	9
85	Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. <i>European Journal of Endocrinology</i> , <b>1994</b> , 131, 14-9	6.5	9
84	Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 375-385	3.5	9
83	One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients. <i>Endocrine</i> , <b>2017</b> , 55, 573-581	4	8
82	Diabetic hepatosclerosis presenting with severe cholestasis. <i>Diabetes Care</i> , <b>2013</b> , 36, e206	14.6	8

81	Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. <i>European Journal of Endocrinology</i> , <b>2011</b> , 164, 335-40	6.5	8
80	In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2003</b> , 18, 895-902	3.9	8
79	Neuroendocrine aspects of immunolymphoproliferative diseases. <i>Annals of Oncology</i> , <b>2001</b> , 12 Suppl 2, S125-30	10.3	8
78	Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies. <i>Neuroendocrinology</i> , <b>1996</b> , 64, 393-7	5.6	8
77	Hypothalamic-pituitary-adrenal axis in neuropsychiatric disorders. <i>Annals of the New York Academy of Sciences</i> , <b>1994</b> , 741, 263-70	6.5	8
76	Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. <i>Journal of Endocrinological Investigation</i> , <b>2020</b> , 43, 1543-1553	5.3	7
75	Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. <i>Pituitary</i> , <b>2012</b> , 15, 215-21	4.3	7
74	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 211-6	3.4	7
73	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. <i>Gynecological Endocrinology</i> , <b>1995</b> , 9, 15-21	2.4	7
72	Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. <i>European Journal of Endocrinology</i> , <b>1995</b> , 133, 189-94	6.5	7
71	Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. <i>Journal of Endocrinological Investigation</i> , <b>2012</b> , 35, 528-34	5.2	7
70	Current diagnostic guidelines for biochemical diagnosis of acromegaly. <i>Minerva Endocrinologica</i> , <b>2004</b> , 29, 207-23	1.9	7
69	Potential indications for somatostatin analogues: immune system and lymphoproliferative disorders. <i>Journal of Endocrinological Investigation</i> , <b>2005</b> , 28, 111-7	5.2	7
68	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 1094-1095	8.9	6
67	Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. <i>Endocrine</i> , <b>2016</b> , 53, 551-7	4	6
66	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. <i>Pituitary</i> , <b>2012</b> , 15, 209-14	4.3	6
65	2. Somatostatin and dopamine receptors. <i>Tumori</i> , <b>2010</b> , 96, 802-805	1.7	6
64	Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. <i>Metabolism: Clinical and Experimental</i> , <b>2007</b> , 56, 699-707	12.7	6

63	(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. <i>Clinical Endocrinology</i> , <b>2002</b> , 56, 713-21	3.4	6
62	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , <b>2001</b> , 54, 97-106	3.4	6
61	Somatostatin receptor expression in thymic tumors. <i>Frontiers in Bioscience - Landmark</i> , <b>2009</b> , 14, 3304-9	2.8	6
60	. <i>Annals of Oncology</i> , <b>2001</b> , 12, 125-130	10.3	6
59	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 563-579	10.5	6
58	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 44, 989-994	5.2	6
57	Replacement therapy and cardiovascular diseases. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 85-90	5.2	6
56	The role of somatostatin receptors in the medical treatment of acromegaly. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36 Suppl 1, S55-9	3.3	5
55	Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. <i>Clinical Endocrinology</i> , <b>2005</b> , 63, 294-7	3.4	5
54	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. <i>European Journal of Endocrinology</i> , <b>2000</b> , 143 Suppl 1, S35-42	6.5	5
53	Height, weight, height velocity of primary school population sample in Campania region. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 142-7	5.2	5
52	Long-term safety and efficacy of Omnitrope in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 669-678	5.2	4
51	Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS). <i>Journal of Endocrinological Investigation</i> , <b>2018</b> , 41, 1259-1266	5.2	4
50	Effect of environment on growth: auxological and hormonal parameters in African and Italian children. <i>Growth Hormone and IGF Research</i> , <b>2009</b> , 19, 238-41	2	4
49	Corticotropin-releasing hormone administration increases alpha-melanocyte-stimulating hormone levels in the inferior petrosal sinuses in a subset of patients with Cushing's disease. <i>Hormone Research</i> , <b>1996</b> , 46, 26-32		4
48	"Present and future of immunotherapy in Neuroendocrine Tumors". <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2021</b> , 22, 615-636	10.5	4
47	Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 789-801	5.6	4
46	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 200-214	7.5	4

45	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. <i>Journal of Endocrinological Investigation</i> , <b>2017</b> , 40, 1265-1269	5.2	3
44	Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse. <i>Therapie</i> , <b>2019</b> , 74, 547-549	3.8	3
43	Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. <i>Clinical Endocrinology</i> , <b>2015</b> , 83, 527-35	3.4	3
42	Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone replacement therapy in adults with growth hormone deficiency. <i>Hormones</i> , <b>2015</b> , 14, 134-41	3.1	3
41	Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects. <i>Journal of Endocrinological Investigation</i> , <b>1997</b> , 20, 513-8	5.2	3
40	Usefulness of [ <sup>111</sup> In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 352-9	5.2	3
39	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. <i>Journal of Endocrinological Investigation</i> , <b>1998</b> , 21, 257-62	5.2	3
38	Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 937-950	5.6	3
37	Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST in Mediating Ligand Effects. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
36	Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 677919	5.7	3
35	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 367-374	3.3	3
34	Somatostatin receptors in the thymus. <i>Annals of Medicine</i> , <b>1999</b> , 31 Suppl 2, 28-33	1.5	3
33	Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. <i>Archives of Endocrinology and Metabolism</i> , <b>2015</b> , 59, 554-8	2.2	2
32	Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , <b>2015</b> , 44, 216-38	3.5	2
31	Diabetes Secondary to Neuroendocrine Gastroenteropancreatic Tumors. <i>Frontiers in Diabetes</i> , <b>2014</b> , 64-76	0.6	2
30	Somatostatin receptor pathophysiology in the neuroendocrine system. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2013</b> , 8, 149-157	4.1	2
29	Acute administration of hexarelin stimulates GH secretion during day and night in normal men. <i>Clinical Endocrinology</i> , <b>1997</b> , 46, 275-9	3.4	2
28	Sympathovagal imbalance in transsexual subjects. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 1014-9	5.2	2

27	Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge. <i>Endocrine Practice</i> , <b>2021</b> , 27, 856-857	3.2	2
26	The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system. <i>Journal of Endocrinological Investigation</i> , <b>2003</b> , 26, 94-102	5.2	2
25	The role of somatostatin analogs in the management of immunoproliferative disease. <i>Journal of Endocrinological Investigation</i> , <b>2003</b> , 26, 103-8	5.2	2
24	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , <b>2022</b> , 14, 2501	6.6	2
23	Cortistatins and Dopastatins <b>2015</b> , 322-334		1
22	Lack of Somatostatin Analogs Effectiveness in Gonadotropin-Secreting Pituitary Adenomas <b>2006</b> , 16, 208-213		1
21	Acromegaly and immune function. <i>NeuroImmune Biology</i> , <b>2002</b> , 247-257		1
20	Further evaluation of IGF-I responsiveness to ACTH in children affected with IGHD. <i>Hormone Research</i> , <b>1992</b> , 38, 150-3		1
19	The effect of sodium restriction on iodine prophylaxis: a review.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1	5.2	1
18	Emerging drugs for the treatment of acromegaly. <i>Expert Opinion on Emerging Drugs</i> , <b>2020</b> , 25, 409-417	3.7	1
17	Safety and effectiveness of Omnitrope <sup>®</sup> in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. <i>Journal of Endocrinological Investigation</i> , <b>2021</b> , 44, 327-337	5.2	1
16	A comparative cross-sectional study on sleep quality in patients with a history of differentiated thyroid carcinoma and its correlation with quality of life. <i>Endocrine</i> , <b>2021</b> , 73, 347-357	4	1
15	Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature.. <i>Journal of Endocrinological Investigation</i> , <b>2022</b> , 1	5.2	0
14	Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length. <i>Pituitary</i> , <b>2021</b> , 1	4.3	0
13	The primary role of radiological imaging in the diagnosis of rare musculoskeletal diseases. Emphasis on ultrasound. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona Sudo</i> <i>ESzop</i> <i>ńska</i> , <b>2019</b> , 19, 187-192	1.1	0
12	GH Replacement in the Elderly: Is It Worth It?. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 680579	5.7	0
11	Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients. <i>Journal of Endocrinological Investigation</i> , <b>2020</b> , 43, 389-393	5.2	0
10	Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up <b>2018</b> , 203-222		

- 9 Le terapie combinate nell'acromegalia: pro e contro. *L Endocrinologo*, **2013**, 14, 71-78 0
- 8 Prostatic Hyperplasia: An Unknown Feature of Acromegaly. *Journal of Urology*, **1998**, 160, 1583-1584 2.5
- 7 A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery?. *Journal of Andrology*, **2008**, 29, 15-9
- 6 Chapter 8 Autoimmunity and the Pituitary Gland. *Handbook of Systemic Autoimmune Diseases*, **2008**, 9, 83-93 0.3
- 5 Somatostatin Control of Immune Functions **2004**, 193-206
- 4 Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. *Expert Opinion on Pharmacotherapy*, **2020**, 21, 2317-2324 4
- 3 Somatostatin and dopamine receptors. *Tumori*, **2010**, 96, 802-5 1.7
- 2 Inibitori dei checkpoint immunitari e patologia tiroidea. *L Endocrinologo*, **2022**, 23, 125-132 0
- 1 Italian Society of Endocrinology Career Award Lecture: from somatostatin to somatostatin analogs. *Journal of Endocrinological Investigation*, **2012**, 35, 869-74 5.2